RecruitingNCT06125795

A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain

Non-interventional Prospective Descriptive Study to Assess the Impact on Patient´s Well-being of Fixed-time Duration (FTD) and Continuous Oral Regimens for Newly Diagnosed and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain

Sponsor

AbbVie

Enrollment

132 participants

Start Date

Nov 6, 2023

Study Type

OBSERVATIONAL

Conditions

Chronic Lymphocytic Leukemia

Summary

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Since in most cases CLL remains an incurable disease, the goals of therapy are to improve quality of life and to prolong survival. This study will evaluate the participant's related outcomes and experience of CLL in adult participants who are treated in the Spain. Study participants will receive oral treatments for CLL as prescribed by their study doctor in accordance with approved local label. Adult participants prescribed various treatments will be enrolled. Around 132 participants will be enrolled in the study in sites in Spain. Participants will receive oral treatments for CLL according to the approved local label. The overall study duration will be 18 months. There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study is tracking how quality of life and daily functioning change over time in people in Spain with chronic lymphocytic leukemia (CLL, a type of blood cancer) who are taking oral medications as part of their standard care. **You may be eligible if:** - You have been diagnosed with chronic lymphocytic leukemia (CLL) - You are currently taking an oral CLL medication (either as first treatment or for relapsed/refractory disease) - Your treatment started roughly 9 months ago (first-line) or 21 months ago (if relapsed/refractory) - You can understand and complete questionnaires **You may NOT be eligible if:** - You are currently receiving chemotherapy or chemoimmunotherapy (not just oral targeted therapy) - Your CLL has transformed into a more aggressive lymphoma (Richter's transformation) - You are already enrolled in another interventional clinical trial - You have a serious medical condition that would make participation unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(25)

HUA - Txagorritxu /ID# 258263

Vitoria-Gasteiz, Alava, Spain

Sant Joan de Deu de Manresa /ID# 258266

Manresa, Barcelona, Spain

Hospital Universitari Mútua Terrassa /ID# 258267

Terrassa, Barcelona, Spain

Hospital Jerez De La Frontera /ID# 258282

Jerez de la Frontera, Cadiz, Spain

Hospital Comarcal de Laredo /ID# 258262

Laredo, Cantabria, Spain

Hospital Universitario Marques de Valdecilla /ID# 258261

Santander, Cantabria, Spain

Hospital Universitario Dr. Negrin /ID# 258285

Las Palmas de Gran Canaria, Las Palmas, Spain

Hospital Universitario de León /ID# 271526

León, Leon, Spain

Hospital Universitario de Fuenlabrada /ID# 258275

Fuenlabrada, Madrid, Spain

Hospital Clinico Universitario Virgen de la Arrixaca /ID# 262173

El Palmar, Murcia, Spain

Hospital Meixoeiro (CHUVI) /ID# 258286

Vigo, Pontevedra, Spain

Hospital de Cabuenes /ID# 263307

Gijón, Principality of Asturias, Spain

Hospital Universitario Central de Asturias /ID# 271508

Oviedo, Principality of Asturias, Spain

Hospital Universitario de Galdakao /ID# 258264

Galdakao, Vizcaya, Spain

Hospital de Sant Joan Despi Moises Broggi /ID# 262284

Barcelona, Spain

Hospital Universitario Reina Sofia /ID# 271507

Córdoba, Spain

Hospital Universitario Virgen de las Nieves /ID# 258280

Granada, Spain

Hospital Lucus Augusti /ID# 271542

Lugo, Spain

Hospital Universitario de La Princesa /ID# 271506

Madrid, Spain

Hospital General Universitario Gregorio Maranon /ID# 258273

Madrid, Spain

Hospital Universitario Fundacion Jimenez Diaz /ID# 258269

Madrid, Spain

Hospital Universitario 12 de Octubre /ID# 258271

Madrid, Spain

Hospital Universitario La Paz /ID# 258270

Madrid, Spain

Hospital General Universitario Morales Meseguer /ID# 258284

Murcia, Spain

Hospital Universitario Virgen Macarena /ID# 258279

Seville, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06125795

Related Trials

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686175 locations

Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:

NCT053718088 locations

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT0509142431 locations

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

NCT04269902629 locations

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

NCT047715728 locations